JP2024516172A - 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法 - Google Patents

間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法 Download PDF

Info

Publication number
JP2024516172A
JP2024516172A JP2023564582A JP2023564582A JP2024516172A JP 2024516172 A JP2024516172 A JP 2024516172A JP 2023564582 A JP2023564582 A JP 2023564582A JP 2023564582 A JP2023564582 A JP 2023564582A JP 2024516172 A JP2024516172 A JP 2024516172A
Authority
JP
Japan
Prior art keywords
subject
cells
ards
stem cells
mlpscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516172A5 (cg-RX-API-DMAC7.html
Inventor
シルヴィウ・イテスク
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901214A external-priority patent/AU2021901214A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2024516172A publication Critical patent/JP2024516172A/ja
Publication of JP2024516172A5 publication Critical patent/JP2024516172A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023564582A 2021-04-23 2022-04-22 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法 Pending JP2024516172A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2021901214 2021-04-23
AU2021901214A AU2021901214A0 (en) 2021-04-23 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
AU2021902180A AU2021902180A0 (en) 2021-07-15 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
AU2021902180 2021-07-15
AU2022900260 2022-02-09
AU2022900260A AU2022900260A0 (en) 2022-02-09 Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells
AU2022900372A AU2022900372A0 (en) 2022-02-18 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
AU2022900372 2022-02-18
PCT/IB2022/053763 WO2022224207A1 (en) 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells

Publications (2)

Publication Number Publication Date
JP2024516172A true JP2024516172A (ja) 2024-04-12
JP2024516172A5 JP2024516172A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=81585202

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023564582A Pending JP2024516172A (ja) 2021-04-23 2022-04-22 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法
JP2023564584A Pending JP2024516173A (ja) 2021-04-23 2022-04-22 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群(ards)を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023564584A Pending JP2024516173A (ja) 2021-04-23 2022-04-22 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群(ards)を治療するための方法

Country Status (8)

Country Link
US (2) US20240207323A1 (cg-RX-API-DMAC7.html)
EP (2) EP4326295A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024516172A (cg-RX-API-DMAC7.html)
KR (2) KR20240001172A (cg-RX-API-DMAC7.html)
AU (2) AU2022261504A1 (cg-RX-API-DMAC7.html)
BR (2) BR112023021840A2 (cg-RX-API-DMAC7.html)
CA (2) CA3216121A1 (cg-RX-API-DMAC7.html)
WO (2) WO2022224207A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAIN PHYSICIAN, vol. Vol.23, pp.E71-E83, JPN6026003112, 2020, ISSN: 0005787939 *
STEM CELLS TRANSL MED., vol. Vol.10, pp.660-673, JPN6026003111, 5 January 2021 (2021-01-05), ISSN: 0005787938 *

Also Published As

Publication number Publication date
EP4326295A1 (en) 2024-02-28
US20240207323A1 (en) 2024-06-27
EP4326294A1 (en) 2024-02-28
JP2024516173A (ja) 2024-04-12
BR112023021825A2 (pt) 2024-02-06
CA3216121A1 (en) 2022-10-27
WO2022224207A1 (en) 2022-10-27
KR20240001173A (ko) 2024-01-03
WO2022224206A1 (en) 2022-10-27
BR112023021840A2 (pt) 2024-02-06
AU2022261504A1 (en) 2023-11-30
CA3216129A1 (en) 2022-10-27
US20240197787A1 (en) 2024-06-20
AU2022260822A1 (en) 2023-11-30
KR20240001172A (ko) 2024-01-03

Similar Documents

Publication Publication Date Title
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
JP2023513847A (ja) 慢性移植片対宿主病の治療方法
CN115361959A (zh) 用于使用间充质谱系前体或干细胞治疗过度炎症的方法
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
WO2023119239A1 (en) Method of treating severe graft versus host disease
JP2023517636A (ja) 炎症性腸疾患を治療するための方法i
AU2021403025A1 (en) Method of treating progressive heart failure in subjects with class ii heart failure
JP2007520233A (ja) 骨髄ストローマ細胞を用いた神経幹細胞の培養に関する組成物と方法
CN117337184A (zh) 使用间充质谱系前体细胞或干细胞治疗急性呼吸窘迫综合征(ards)的方法
JP2022513475A (ja) Hla-eを発現する肝臓前駆細胞を含む細胞組成物
WO2025046491A1 (en) Third line treatment for gvhd
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260507